


## United Global Healthcare Fund

### Fund Performance

In the month of April 2017, the performance of the United Global Healthcare Fund (the "Fund") rose by 0.88%<sup>1</sup> while its benchmark, MSCI ACWI Healthcare Index, increased 1.88%<sup>2</sup>.



### Performance Attribution

The Fund underperformed the MSCI ACWI Healthcare Index for the month.

Security selection in mid-cap biopharmaceuticals detracted from performance, though this was partly offset by the Fund's overweight to the relatively strongly performing sub-sector. The shares of a US-based oncology-focused company came under pressure after some modestly disappointing pipeline news and lower-than-expected pricing on a new drug launch. Meanwhile, Agios Pharmaceuticals stock moved lower following a \$250 million equity raise. The portfolio's collection of off-benchmark small-cap biopharmaceutical stocks detracted as Infinity Pharmaceuticals (oncology) weighed on overall performance.

In health care services, stock selection detracted. A provider of cloud-based medical records and network services reported disappointing first-quarter results and lowered guidance. The miss was attributed to a larger-than-expected drop in patient visits and modestly lower payments per visit. The medical technology space was additive to overall performance. Boston Scientific's shares outperformed as the medical device maker reported strong quarterly results, with revenue growth across all segments and regions.

In the large-cap biopharma space, the Fund benefited from not holding several benchmark stocks that underperformed during the month, including Johnson & Johnson, Pfizer and GlaxoSmithKline. Stock selection in

<sup>1</sup> Source: Lipper, Performance from 31 March 2017 to 28 April 2017 in SGD terms, on a NAV (Net Asset Value) basis, with dividends and distributions reinvested (if any).

<sup>2</sup> Source: Lipper, Performance from 31 March 2017 to 28 April 2017 in SGD terms.

<sup>3</sup> Top 10 holdings of the Fund are UnitedHealth Group, Allergan Plc, Bristol Myers, Alkermes Plc, Boston Scientific Corporation, Astrazeneca, Eli Lilly, Medtronic Plc, Portola Pharmaceuticals, and Incyte Corp

All statistics quoted in the write-up are sourced from Bloomberg as at 28 April 2017 unless otherwise stated.

## United Global Healthcare Fund

---

the space detracted from performance. Incyte's shares fell on news of a regulatory delay in the approval process for the firm's phase 3 rheumatoid arthritis drug

### Outlook and Strategy

While we expect the lack of clarity about the path forward for policy to continue for some time, we remain convinced that full repeal of the Affordable Care Act (ACA) will not occur without the introduction of an alternative plan to accommodate the more than 20 million Americans newly insured by the ACA. Changes in health care policy and regulation have affected, and will almost certainly continue to affect, the performance of health care stocks in the short and medium term. Over the longer term, however, we think market forces – such as greater transparency and better alignment of incentives – and an intensifying focus on evidenced-based medicine and value-based care will have a more significant impact.

To that end, we seek to populate our portfolio with stocks of companies which offer differentiated innovation and a true value proposition, specifically one that optimises for both quality and affordability. We believe these are the companies that should thrive over the long term in an environment of regulatory and political changes, with the greater exertion of market forces.

## Contact Details

### SINGAPORE

#### UOB Asset Management Ltd

**Address** 80 Raffles Place UOB Plaza 2 Level 3 Singapore 048624  
**Tel** 1800 222 2228 (Local) • (65) 6222 2228 (International)  
**Fax** (65) 6532 3868  
**Email** [uobam@uobgroup.com](mailto:uobam@uobgroup.com)  
**Website** [uobam.com.sg](http://uobam.com.sg)

---

### MALAYSIA

#### UOB Asset Management (Malaysia) Berhad

**Address** Level 22, Vista Tower, The Intermark  
No. 348 Jalan Tun Razak, 50400 Kuala Lumpur  
**Tel** (03) 2732 1181  
**Fax** (03) 2164 8188  
**Website** [uobam.com.my](http://uobam.com.my)

---

### THAILAND

#### UOB Asset Management (Thailand) Co., Ltd

**Address** 23A, 25 Floor, Asia Centre Building, 173/27-30, 32-33  
South Sathon Road, Thungmahamek, Sathon, Bangkok 10120, Thailand  
**Tel** (66) 2786 2000  
**Fax** (66) 2786 2377  
**Website** [uobam.co.th](http://uobam.co.th)

---

### BRUNEI

#### UOB Asset Management (B) Sdn Bhd

**Address** FF03 to FF05, The Centrepont Hotel, Gadong,  
Bandar Seri Begawan BE 3519, Brunei Darussalam  
**Tel** (673) 2424806  
**Fax** (673) 2424805

---

### TAIWAN

#### UOB Asset Management (Taiwan) Co., Ltd

**Address** Union Enterprise Plaza, 16th Floor, 109 Minsheng East Road, Section 3,  
Taipei 10544  
**Tel** (886)(2) 2719 7005  
**Fax** (886)(2) 2545 6591

---

### JAPAN

#### UOB Asset Management (Japan) Ltd

**Address** 13F Sanno Park Tower, 2-11-1 Nagatacho, Chiyoda-ku,  
Tokyo 100-6113 Japan  
**Tel** (813) 3500-5981  
**Fax** (813) 3500-5985

## Important Notice and Disclaimers

All information in this publication is based upon certain assumptions and analysis of information available as at the date of the publication and reflects prevailing conditions and UOB Asset Management Ltd (“UOBAM”)’s views as of such date, all of which are subject to change at any time without notice. Although care has been taken to ensure the accuracy of information contained in this publication, UOBAM makes no representation or warranty of any kind, express, implied or statutory, and shall not be responsible or liable for the accuracy or completeness of the information.

Potential investors should read the prospectus of the fund(s) (the “Fund(s)”) which is available and may be obtained from UOBAM or any of its appointed distributors, before deciding whether to subscribe for or purchase units in the Fund(s). Returns on the units are not guaranteed. The value of the units and the income from them, if any, may fall as well as rise. Please note that the graphs, charts, formulae or other devices set out or referred to in this document cannot, in and of itself, be used to determine and will not assist any person in deciding which investment product to buy or sell, or when to buy or sell an investment product. An investment in the Fund(s) is subject to investment risks and foreign exchange risks, including the possible loss of the principal amount invested. Investors should consider carefully the risks of investing in the Fund(s) and may wish to seek advice from a financial adviser before making a commitment to invest in the Fund(s). Should you choose not to seek advice from a financial adviser, you should consider carefully whether the Fund(s) is suitable for you. Investors should note that the past performance of any investment product, manager, company, entity or UOBAM mentioned in this publication, and any prediction, projection or forecast on the economy, stock market, bond market or the economic trends of the markets is not necessarily indicative of the future or likely performance of any investment product, manager, company, entity or UOBAM or the economy, stock market, bond market or economic trends of the markets. Nothing in this publication shall constitute a continuing representation or give rise to any implication that there has not been or that there will not be any change affecting the Funds. All subscription for the units in the Fund(s) must be made on the application forms accompanying the prospectus of that fund.

The above information is strictly for general information only and is not an offer, solicitation advice or recommendation to buy or sell any investment product or invest in any company. This publication should not be construed as accounting, legal, regulatory, tax, financial or other advice. Investments in unit trusts are not obligations of, deposits in, or guaranteed or insured by United Overseas Bank Limited, UOBAM, or any of their subsidiary, associate or affiliate or their distributors. The Fund(s) may use or invest in financial derivative instruments and you should be aware of the risks associated with investments in financial derivative instruments which are described in the Fund(s)’ prospectus.

In the event of any discrepancy between the English and Mandarin versions of this publication, the English version shall prevail.

**UOB Asset Management Ltd Co. Reg. No. 198600120Z**